UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription

Genes & development, 2000-10, Vol.14 (19), p.2452-2460

2000

Volltextzugriff (PDF)

A novel arsenical has antitumor activity toward AS2O3-resistant and MRP1/ABCC1-overexpressing cell lines

Leukemia, 2008-10, Vol.22 (10), p.1853-1863

2008

Volltextzugriff (PDF)

Safety and Tolerability of Veliparib Combined With Capecitabine Plus Radiation Therapy in Patients With Locally Advanced Rectal Cancer: Final Results of a Phase 1b Study

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.S206-S206

2015

Volltextzugriff (PDF)

TFIID-specific yeast TAF40 is essential for the majority of RNA polymerase II-mediated transcription in vivo

Genes & development, 1999-10, Vol.13 (19), p.2484-2489

1999

Volltextzugriff (PDF)

608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors

European journal of cancer (1990), 2012-11, Vol.48, p.187-187

2012

Volltextzugriff (PDF)

Erratum: A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines

Leukemia, 2009-02, Vol.23 (2), p.431-431

2009

Volltextzugriff (PDF)

1414TiP Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort

Annals of oncology, 2020-09, Vol.31, p.S894-S894

2020

Volltextzugriff (PDF)

The Essential Interaction between Yeast mRNA Capping Enzyme Subunits Is Not Required for Triphosphatase Function In Vivo

Molecular and Cellular Biology, 2000-12, Vol.20 (24), p.9307-9316

2000

Volltextzugriff (PDF)

P2.01-19 Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET+ Non-Small Cell Lung Cancer: Trial in Progress

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S646-S646

2019

Volltextzugriff (PDF)

1739OA phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

A phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC)

Annals of oncology, 2019-10, Vol.30, p.v711-v712

2019

Volltextzugriff (PDF)

1739O - A phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC)

Annals of oncology, 2019-10, Vol.30, p.v711-v712

2019

Volltextzugriff (PDF)

P1.04-007 Rovalpituzumab Tesirine Maintenance Therapy Following 1st Line Platinum-Based Chemotherapy Small Cell Lung Cancer

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1975-S1975

2017

Volltextzugriff (PDF)

1748PPhase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

ADR1 Activation Domains Contact the Histone Acetyltransferase GCN5 and the Core Transcriptional Factor TFIIB

The Journal of biological chemistry, 1996-12, Vol.271 (50), p.32359-32365

1996

Volltextzugriff (PDF)

Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer

Annals of oncology, 2019-10, Vol.30, p.v715-v716

2019

Volltextzugriff (PDF)

1748P - Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer

Annals of oncology, 2019-10, Vol.30, p.v715-v716

2019

Volltextzugriff (PDF)

P1.04-006 Rovalpituzumab Tesirine vs Topotecan in Patients with Advanced Small Cell Lung Cancer Following 1st Line Chemotherapy

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1974-S1975

2017

Volltextzugriff (PDF)

A phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy

Annals of oncology, 2017-09, Vol.28, p.v542

2017

Volltextzugriff (PDF)

MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S305-S306

2019

Volltextzugriff (PDF)

205PEFFICACY ANALYSIS OF GEFITINIB +/- FICLATUZUMAB IN SERUM PROTEOMIC BASED SUBGROUPS OF PATIENTS WITH PREVIOUSLY UNTREATED LUNG ADENOCARCINOMA

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv70-iv70

2014

Volltextzugriff (PDF)

Efficacy Analysis of Gefitinib +/- Ficlatuzumab in Serum Proteomic Based Subgroups of Patients with Previously Untreated Lung Adenocarcinoma

Annals of oncology, 2014-09, Vol.25, p.iv70

2014

Volltextzugriff (PDF)

Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin

Anti-cancer drugs, 2012-02, Vol.23 (2), p.173-184

2012

Volltextzugriff (PDF)

ADR1-Mediated Transcriptional Activation Requires the Presence of an Intact TFIID Complex

Molecular and Cellular Biology, 1998-10, Vol.18 (10), p.5861-5867

1998

Volltextzugriff (PDF)

Histone-like TAFs Are Essential for Transcription In Vivo

Molecular cell, 1998-11, Vol.2 (5), p.663-673

1998

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(40)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription

A novel arsenical has antitumor activity toward AS2O3-resistant and MRP1/ABCC1-overexpressing cell lines

Safety and Tolerability of Veliparib Combined With Capecitabine Plus Radiation Therapy in Patients With Locally Advanced Rectal Cancer: Final Results of a Phase 1b Study

TFIID-specific yeast TAF40 is essential for the majority of RNA polymerase II-mediated transcription in vivo

608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors

Erratum: A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines

1414TiP Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort

The Essential Interaction between Yeast mRNA Capping Enzyme Subunits Is Not Required for Triphosphatase Function In Vivo

P2.01-19 Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET+ Non-Small Cell Lung Cancer: Trial in Progress

1739OA phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC)

A phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC)

1739O - A phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC)

P1.04-007 Rovalpituzumab Tesirine Maintenance Therapy Following 1st Line Platinum-Based Chemotherapy Small Cell Lung Cancer

1748PPhase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer

ADR1 Activation Domains Contact the Histone Acetyltransferase GCN5 and the Core Transcriptional Factor TFIIB

Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer

1748P - Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer

P1.04-006 Rovalpituzumab Tesirine vs Topotecan in Patients with Advanced Small Cell Lung Cancer Following 1st Line Chemotherapy

A phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy

MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer

205PEFFICACY ANALYSIS OF GEFITINIB +/- FICLATUZUMAB IN SERUM PROTEOMIC BASED SUBGROUPS OF PATIENTS WITH PREVIOUSLY UNTREATED LUNG ADENOCARCINOMA

Efficacy Analysis of Gefitinib +/- Ficlatuzumab in Serum Proteomic Based Subgroups of Patients with Previously Untreated Lung Adenocarcinoma

Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin

ADR1-Mediated Transcriptional Activation Requires the Presence of an Intact TFIID Complex

Histone-like TAFs Are Essential for Transcription In Vivo

Suchergebnisse filtern